论文部分内容阅读
目的探讨重组人脑利钠肽治疗顽固性心力衰竭的治疗效果。方法将70例顽固性心力衰竭患者按照治疗方法不同分为重组人脑利钠肽治疗组(实验1组)与硝普钠治疗组(实验2组),每组35例。观察两组患者治疗效果与不良反应发生情况。结果实验1组治疗疗效优于实验2组,差异有统计学意义(P<0.05);两组治疗后各项指标变化,较治疗前差异均有统计学意义(P<0.05);治疗后,实验1组各项指标变化优于实验2组,差异有统计学意义(P<0.05)。结论采用重组人脑利钠肽治疗顽固性心力衰竭,治疗效果好,且安全性高。
Objective To investigate the therapeutic effect of recombinant human brain natriuretic peptide in patients with refractory heart failure. Methods Seventy patients with refractory heart failure were divided into three groups according to the treatment: recombinant human brain natriuretic peptide (experimental group 1) and sodium nitroprusside (experimental group 2), 35 cases in each group. Observation of two groups of patients with treatment and adverse reactions occurred. Results The curative effect of experimental group 1 was better than that of experimental group 2, the difference was statistically significant (P <0.05). The changes of each index after treatment in both groups were statistically significant (P <0.05). After treatment, The changes of each index in experiment 1 group were better than those in experimental group 2, the difference was statistically significant (P <0.05). Conclusion Recombinant human brain natriuretic peptide is effective in treating refractory heart failure with high safety.